Related Experiment Videos
Enhancing the avidity of a human recombinant anti-HIV-1 monoclonal antibody through oligomerization
P K Tsai1, C J Burke, J W Irwin
1Department of Pharmaceutical Research, Merck Research Laboratories, West Point, PA 19486, USA.
Abstract:
The oligomerization by chemical cross-linking of a recombinant human antiviral monoclonal antibody (MAb), r447-1, and its characterization are described. This MAb binds to an epitope residing in the hypervariable V3 region of the envelope protein (gp120/160) of HIV-1. A dimeric form of this MAb displays enhanced avidity and was found to be capable of neutralizing a greater variety of lymphoid cell culture-adapted HIV-1 variants and HIV-1 primary isolates than its monomeric form. The superior binding and breadth of reactivity of this antibody suggests it may have utility as a therapeutic and/or prophylactic agent, if it possesses an appropriate safety and immunogenicity profile.